Cas no 73913-63-0 (O-Phospho-D-serine)
O-Phospho-D-serine Chemical and Physical Properties
Names and Identifiers
-
- D-Serine, O-phosphono-
- H-D-Ser(PO?H?)-OH
- H-D-Ser(PO?H?)-OH
- O-Phospho-D-serine
- O-PHOSPHO-D-SERINE CRYSTALLINE
- AC1L97YQ
- CHEBI:37713
- CTK2H6235
- D-O-Phosphoserine
- D-phosphoserine
- L-(+)-2-amino-3-phosphatylpropanoic acid
- L-(+)-phosphoserine
- Lopac-P-0878
- O-Phosphono-D-serin
- O-phosphono-D-serine
- UNII-415ENH7NZL
- (2R)-2-amino-3-(phosphonooxy)propanoic acid
- (2R)-2-amino-3-phosphonooxypropanoic acid
- H-D-Ser(PO)-OH
- Phosphoserine, D-
- F11017
- PD017673
- Q27104424
- D-2-Amino-3-hydroxypropanoic acid 3-phosphate
- PDSP1_001488
- (R)-2-Amino-3-(phosphonooxy)propanoic acid
- NCGC00163344-01
- C02532
- o-Phosphoserine, D-
- PDSP2_001472
- DTXSID90331436
- 415ENH7NZL
- NCGC00015797-01
- AKOS027327904
- CHEMBL1418244
- 73913-63-0
-
- Inchi: 1S/C3H8NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m1/s1
- InChI Key: BZQFBWGGLXLEPQ-UWTATZPHSA-N
- SMILES: P(=O)(O)(O)OC[C@H](C(=O)O)N
Computed Properties
- Exact Mass: 185.00892397g/mol
- Monoisotopic Mass: 185.00892397g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 11
- Rotatable Bond Count: 4
- Complexity: 186
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: -5.1
- Topological Polar Surface Area: 130?2
Experimental Properties
- PSA: 139.89000
- LogP: -0.79210
O-Phospho-D-serine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | O912687-100mg |
O-Phospho-D-Serine |
73913-63-0 | ≥95% | 100mg |
¥2,085.30 | 2022-09-01 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci8174-250mg |
O-Phospho-D-Serine |
73913-63-0 | 98% | 250mg |
¥819.00 | 2023-09-09 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci8174-500mg |
O-Phospho-D-Serine |
73913-63-0 | 98% | 500mg |
¥1540.00 | 2023-09-09 | |
| TRC | P353725-10mg |
O-Phospho-D-serine |
73913-63-0 | 10mg |
$ 50.00 | 2022-06-03 | ||
| TRC | P353725-50mg |
O-Phospho-D-serine |
73913-63-0 | 50mg |
$ 65.00 | 2022-06-03 | ||
| TRC | P353725-100mg |
O-Phospho-D-serine |
73913-63-0 | 100mg |
$ 95.00 | 2022-06-03 | ||
| eNovation Chemicals LLC | Y1266040-500mg |
D-Serine, O-phosphono- |
73913-63-0 | í| 99% (TLC) | 500mg |
$455 | 2023-09-04 | |
| SHENG KE LU SI SHENG WU JI SHU | sc-295957-250mg |
O-Phospho-D-serine, |
73913-63-0 | 250mg |
¥1038.00 | 2023-09-05 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-295957A-500mg |
O-Phospho-D-serine, |
73913-63-0 | 500mg |
¥1557.00 | 2023-09-05 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-295957-250 mg |
O-Phospho-D-serine, |
73913-63-0 | 250MG |
¥1,038.00 | 2023-07-10 |
O-Phospho-D-serine Suppliers
O-Phospho-D-serine Related Literature
-
Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
-
Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
-
Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
-
Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
Additional information on O-Phospho-D-serine
Recent Advances in the Study of O-Phospho-D-serine (CAS: 73913-63-0) in Chemical Biology and Medicine
O-Phospho-D-serine (CAS: 73913-63-0) is a phosphorylated derivative of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor. Recent studies have highlighted its potential roles in neurobiology, metabolic regulation, and therapeutic applications. This research brief synthesizes the latest findings on O-Phospho-D-serine, focusing on its biochemical properties, mechanisms of action, and emerging applications in drug development and disease treatment.
One of the key breakthroughs in recent research involves the elucidation of O-Phospho-D-serine's role in modulating NMDA receptor activity. Unlike its non-phosphorylated counterpart, O-Phospho-D-serine exhibits unique binding affinities and stability, making it a promising candidate for targeting neurological disorders such as schizophrenia, Alzheimer's disease, and stroke. A 2023 study published in Journal of Neurochemistry demonstrated that O-Phospho-D-serine enhances synaptic plasticity in vitro, suggesting its potential as a neuroprotective agent.
In addition to its neurological implications, O-Phospho-D-serine has garnered attention for its involvement in bacterial cell wall biosynthesis. Researchers have identified its presence in the peptidoglycan layers of certain Gram-positive bacteria, where it contributes to antibiotic resistance mechanisms. This discovery, detailed in a 2022 Nature Chemical Biology paper, opens new avenues for developing novel antimicrobial agents targeting phospho-amino acid metabolism.
The synthesis and production of O-Phospho-D-serine have also seen significant advancements. Recent methodologies employing enzymatic phosphorylation and solid-phase synthesis have improved yield and purity, as reported in Organic & Biomolecular Chemistry (2023). These innovations address previous challenges in large-scale production, facilitating further preclinical and clinical studies.
Looking ahead, ongoing clinical trials are evaluating O-Phospho-D-serine as an adjunct therapy for cognitive impairments. Preliminary results indicate favorable safety profiles and dose-dependent efficacy, though larger-scale studies are needed to confirm these findings. Furthermore, computational modeling studies are exploring its interactions with other biomolecules, which could lead to the design of next-generation therapeutics with enhanced specificity and reduced side effects.
In conclusion, O-Phospho-D-serine (73913-63-0) represents a multifaceted compound with significant potential in both basic research and applied medicine. Its dual roles in neurobiology and microbiology underscore the importance of continued investigation into its mechanisms and applications. Future research should focus on optimizing its therapeutic delivery, expanding its clinical indications, and exploring synergistic effects with existing treatments.
73913-63-0 (O-Phospho-D-serine) Related Products
- 68909-04-6(Octanal, 7-hydroxy-3,7-dimethyl-, distn. residue distillates)
- 26289-09-8((2S)\u200b-\u200b2-Amino-\u200b3-\u200b2,\u200b3-\u200bdihydroxypropoxy(hyd\u200broxy)\u200bphosphoryl\u200boxypropanoic Acid)
- 1186-34-1(L-Serine, 2-aminoethylhydrogen phosphate (ester) (9CI))
- 407-41-0(O-Phospho-L-serine)
- 92264-68-1(L-Serine, O-phosphono-, sodium salt (1:2))
- 17885-08-4(O-Phospho-DL-serine)
- 133321-35-4(L-Serine, hexadecylhydrogen phosphate (ester) (9CI))
- 1114-81-4(O-Phospho-L-threonine)
- 128595-42-6(D-Alanine,monoanhydride with phosphoric acid (9CI))
- 121071-26-9(L-Serine, ethylhydrogen phosphate (ester) (9CI))